Royds J A, Iacopetta B
Department of Pathology, University of Otago, Dunedin, New Zealand.
Cell Death Differ. 2006 Jun;13(6):1017-26. doi: 10.1038/sj.cdd.4401913.
The p53 tumor suppressor gene (TP53) is mutated more often in human cancers than any other gene yet reported. Of importance, it is mutated frequently in the common human malignancies of the breast and colorectum and also, but less frequently, in other significant human cancers such as glioblastomas. There is also one inherited cancer predisposing syndrome called Li-Fraumeni that is caused by TP53 mutations. In this review, we discuss the significance of p53 mutations in some of the above tumors with a view to outlining how p53 contributes to malignant progression. We also discuss the usefulness of TP53 status as a prognostic marker and its role as a predictor of response to therapy. Finally, we outline some evidence that abnormalities in p53 function contribute to the etiology of other non-neoplastic diseases.
p53肿瘤抑制基因(TP53)在人类癌症中的突变频率高于迄今报道的任何其他基因。重要的是,它在乳腺癌和结直肠癌等常见人类恶性肿瘤中频繁突变,在其他重要的人类癌症如胶质母细胞瘤中也有突变,但频率较低。还有一种遗传性癌症易感综合征叫李-佛美尼综合征,它由TP53突变引起。在本综述中,我们讨论p53突变在上述某些肿瘤中的意义,以期概述p53如何促进恶性进展。我们还讨论TP53状态作为预后标志物的有用性及其作为治疗反应预测指标的作用。最后,我们概述一些证据,证明p53功能异常导致其他非肿瘤性疾病的病因。